Höbel S, Dautel P, Baumbach R, Oldhafer K-J, Stang A, Feyerabend B, Yahagi N, Schrader C, Faiss S
Department of Gastroenterology & Interventional Endoscopy; Asklepios Hospital Barmbek, Medical Faculty, Semmelweis University, Campus Hamburg, Rübenkamp 220, 22291, Hamburg, Germany.
Surg Endosc. 2015 Jun;29(6):1591-7. doi: 10.1007/s00464-014-3847-5. Epub 2014 Oct 8.
Endoscopic mucosal resection (EMR) or radical surgical resection are the standard treatment options for patients with early Barrett's adenocarcinoma (EBAC). Endoscopic submucosal dissection (ESD) is a new endoscopic technique, which allows--in contrast to EMR--endoscopic en-bloc resection of neoplastic lesions greater than 2 cm with complete histological evaluation of the resected specimen. In contrast to Western countries, Barrett's esophagus is less common in Asia indicating the low volume of published data of ESD in EBAC in Japanese series. Therefore, the aim of the present study is to describe the results of ESD in patients with EBAC performed in a German tertiary referral center.
Between November 2009 and April 2014 ESDs were performed in 22 patients with histologically proven EBAC. Data were given for the en-bloc, the R0, the R0 en-bloc, and the curative resection rate as well as for the complication and the local recurrence rate.
ESD was technically possible in all of the 22 patients. 20 of the resected EBAC were mucosal carcinomas, whereas in two patients the tumor showed submucosal invasion. The en-bloc, R0, R0 en-bloc, and curative resection rates were 95.5, 81.8, 81.8 %, and 77.3 %, resp. Complication rate was 27.3 % (perforation n = 1, bleeding n = 2, stenosis n = 3). In case of curative tumor resection, only one local tumor recurrence (5.9 %) occurred after a medium follow-up of 1.6 years.
Despite the small number of patients and a relatively short follow-up, the present data underline the value of ESD, especially in case of curative resections in the definite and less invasive therapy of EBAC. Attention should be drawn toward subsquamous extension of EBAC requiring a sufficient safety margin as an obligate condition for curative R0 resections. Due to the required learning curve and the management of potential complications, ESD should be restricted to greater endoscopic centers.
内镜黏膜切除术(EMR)或根治性手术切除是早期巴雷特腺癌(EBAC)患者的标准治疗选择。内镜黏膜下剥离术(ESD)是一种新的内镜技术,与EMR不同,它能对大于2cm的肿瘤性病变进行内镜整块切除,并对切除标本进行完整的组织学评估。与西方国家相比,巴雷特食管在亚洲较少见,这表明日本系列中关于EBAC的ESD发表数据量较少。因此,本研究的目的是描述在德国一家三级转诊中心对EBAC患者进行ESD的结果。
2009年11月至2014年4月期间,对22例经组织学证实为EBAC的患者进行了ESD。给出了整块切除率、R0切除率、R0整块切除率、根治性切除率以及并发症和局部复发率的数据。
22例患者均成功进行了ESD。切除的EBAC中,20例为黏膜癌,2例肿瘤侵犯黏膜下层。整块切除率、R0切除率、R0整块切除率和根治性切除率分别为95.5%、81.8%、81.8%和77.3%。并发症发生率为27.3%(穿孔1例,出血2例,狭窄3例)。在根治性肿瘤切除的情况下,中位随访1.6年后仅发生1例局部肿瘤复发(5.9%)。
尽管患者数量较少且随访时间相对较短,但目前的数据强调了ESD的价值,特别是在对EBAC进行确定性和微创治疗的根治性切除方面。应注意EBAC的黏膜下扩展,为实现根治性R0切除,需要足够的安全切缘。由于需要学习曲线和处理潜在并发症,ESD应仅限于较大的内镜中心。